United States Multiomics Market by Region, Competition, Forecast & Opportunities, 2020-2030F

The United States Multiomics Market was valued at USD 1.03 Billion in 2024, and is projected to reach USD 1.39 Billion by 2030, rising at a CAGR of 5.28%. Multiomics integrates data from multiple molecular layers to offer a more holistic view of health, disease, and drug response, making it a powerful tool in precision medicine, drug discovery, and clinical diagnostics. In the U.S., this market is expanding due to strong investment in life sciences research, increasing adoption of personalized healthcare, and the availability of advanced technological platforms.

Academic institutions, biotechnology firms, and pharmaceutical companies are leveraging multiomics to uncover complex disease mechanisms, identify novel biomarkers, and develop more targeted therapies. Despite its potential, the U.S. multiomics market faces challenges, particularly in terms of data integration, standardization, and interpretation. Managing large, complex datasets across different omics platforms requires robust bioinformatics capabilities and advanced computational infrastructure. There is also a growing need for skilled professionals who can bridge the gap between molecular biology and data science.

Key Market Drivers

Growth in Healthcare Industry

The growth of the healthcare industry in the United States is a major driver of the expanding multiomics market. In 2023, U.S. healthcare expenditures increased by 7.5%, reaching a total of USD 4.9 trillion, equivalent to approximately USD 14,570 per capita. This spending represented 17.6% of the country’s Gross Domestic Product (GDP). As the sector shifts toward precision medicine and data-driven care, the demand for comprehensive, multi-layered biological analysis has surged. Multiomics, an integrated approach that combines genomics, proteomics, transcriptomics, metabolomics, and other “omics” technologies is increasingly seen as essential to understanding complex diseases and tailoring more effective treatments.

One of the most significant factors fueling this demand is the healthcare industry’s emphasis on personalized medicine. For instance, USP, headquartered in Maryland, is committed to ensuring a reliable and consistent supply of safe, high-quality medicines. Leveraging scientific expertise and capacity-building solutions, USP develops standards, practical tools, and resources that empower healthcare professionals to deliver optimal personalized care across all healthcare environments. With a growing focus on treatments that are customized to an individual’s unique biological profile, healthcare providers and researchers are turning to multiomics to uncover deeper molecular insights.

Key Market Challenges

Asymptomatic Nature of HSV Infections

The asymptomatic nature of HSV infections presents a unique challenge for the United States multiomics market, particularly in efforts to develop diagnostic tools and personalized treatment strategies. Since a significant proportion of individuals infected with Herpes Simplex Virus do not exhibit noticeable symptoms, detecting and studying the virus becomes inherently difficult. This silent transmission complicates sample collection and patient identification, which are critical for generating meaningful multiomics data.

In multiomics research, comprehensive biological data from infected individuals is essential to understand the molecular mechanisms of infection, immune response, and viral latency. However, the asymptomatic presentation often results in underdiagnosis and underreporting, limiting the availability of well-characterized clinical samples. This scarcity hampers the ability to identify reliable biomarkers or molecular signatures associated with different stages of HSV infection.

Key Market Trends

Expansion of Home Testing

The expansion of home testing is an emerging trend significantly influencing the United States multiomics market. For instance, at-home over-the-counter (OTC) COVID-19 diagnostic tests can determine the presence of an active COVID-19 infection. These tests are FDA-authorized for self-administration without a prescription, either at home or in other non-clinical settings. As consumers increasingly seek convenient, accessible, and personalized healthcare solutions, the integration of multiomics technologies into home-based testing platforms is gaining momentum. This trend aligns with the broader shift toward patient-centric care and digital health innovation within the U.S. healthcare landscape.

Home testing powered by multiomics enables individuals to gain comprehensive insights into their genetic, proteomic, and metabolic profiles without the need for frequent clinical visits. Advances in sample collection methods, such as minimally invasive kits for saliva, blood, or urine, combined with robust analytical technologies, have made it feasible to perform complex multiomic analyses outside traditional laboratory settings. This accessibility enhances early disease detection, wellness monitoring, and personalized health management directly in the consumer’s home.

Key Market Players

Becton, Dickinson and Company
Thermo Fisher Scientific Inc.
Illumina, Inc
Danaher Corporation
PerkinElmer Inc.
Shimadzu Corporation
Bruker Corporation
Agilent Technologies, Inc.

Report Scope

In this report, the United States Multiomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

United States Multiomics Market, By Product & Service:

Instruments
Consumables
Software
Services

United States Multiomics Market, By Platform:

Genomics
Transcriptomics
Proteomics
Metabolomics
Integrated Omics Platforms